Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
28 441 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32020R1182

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

NAŘÍZENÍ XXXXXX X XXXXXXXXX XXXXXXXXX (XX) 2020/1182

xx dne 19. xxxxxx 2020,

xxxxxx xx xxx xxxxx xxxxxxxxxxxx xxxxxxxxxxx x vědeckému xxxxxxx xxxx xxxx 3 přílohy XX xxxxxxxx Evropského parlamentu x Xxxx (XX) x. 1272/2008 x xxxxxxxxxxx, xxxxxxxxxx a xxxxxx látek x xxxxx

(Xxxx x xxxxxxxx xxx XXX)

XXXXXXXX XXXXXX,

x xxxxxxx xx Smlouvu x xxxxxxxxx Xxxxxxxx xxxx,

x xxxxxxx xx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (XX) x. 1272/2008 xx xxx 16. prosince 2008 x klasifikaci, xxxxxxxxxx a balení xxxxx x xxxxx, x xxxxx x xxxxxxx směrnic 67/548/XXX x 1999/45/ES x x xxxxx nařízení (XX) x. 1907/2006&xxxx;(1), x xxxxxxx na xx. 37 odst. 5 xxxxxxxxx nařízení,

vzhledem x těmto důvodům:

(1)

Tabulka 3 v xxxxx 3 xxxxxxx XX xxxxxxxx (ES) x. 1272/2008 xxxxxxxx xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxxxxx xxxxx xx základě xxxxxxxx xxxxxxxxxxx x xxxxxxx 2 xx 5 xxxxxxx I uvedeného xxxxxxxx.

(2)

Xxxxxxxx xxxxxxxx pro xxxxxxxx xxxxx („xxxxxxxx“) xxxx x souladu x xxxxxxx 37 xxxxxxxx (ES) č. 1272/2008 xxxxxxxxxx xxxxxx xx zavedení xxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx látek x xxxxxxxxxxx xxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxxx xxxxx. Xx xxxxxxx xxxxxxxxxx&xxxx;(2) k xxxxx xxxxxxx, xxxxx xxxxx Xxxxx xxx xxxxxxxxxx xxxxx („XXX“) xxxxxxxx, xxxxx i xxxxxxxxxx xxxxxxxxxxxx stran, xx xxxxxx xxxxxx, xxxxxxxxxxxx xx xxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxx. Uvedená xxxxxxxxxx xxxxxx XXX xxxx:

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx kyseliny xxxxxxx... %[X ≤ 70 %],

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxx x xxxxxxx křemíku (x xxxxxxx < 3 μx,xxxxx &xx; 5 μx x xxxxxx xxxxx ≥ 3:1),

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 ohledně xxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxx(xxxxx)xxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxxx, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—

xxxxxxxxxx ze dne 8. xxxxxx 2018 xxxxxxx dimethyl-disulfidu,

—

stanovisko xx xxx 8. xxxxxx 2018 ohledně xxxxxxxxxxx xxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx bis (X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)-xxxx, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Xx-XXX],

—

xxxxxxxxxx xx xxx 14. září 2018 ohledně xxxxxxxxxx-xxxxxxxxx, [1] xxxxxxxx, dioktyl-, xxx(xxxx acyloxy) xxxxxxxx [2],

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx xxxxxxx[xxx,x]xxxxxxxx, xxxxxxx[x,x]xxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxx (ISO), (1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 ohledně xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx xxxxxxxxxxxxxx (XXX), (2XX,3XX)-1-(4-xxxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xxx,

—

xxxxxxxxxx xx xxx 8. června 2018 ohledně 2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 ohledně xxxxxxxxx, (2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xxx,

—

xxxxxxxxxx xx xxx 28. xxxxx 2019 ohledně 2-(4-xxxx-xxxxxxxxxxx)xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně XXXX-xxxxxxxxxx (XXX), S-ethyl (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, X-xxxxx 4-chlor-o-tolyloxythioacetátu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx 4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-onu, xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx-xxxxxxx (XXX), xxxxxx 4- [(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx X-(+)-xxxxxx xxxxxxxx, (2X)-2-xxxxxxxxxxxxxxxx xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx 2-xxxxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxx kyseliny …%,

—

xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx, [formaldehyd xxxxxxxx x xxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně (xxxxx-XXX-xxxxx)xxxxxxxxxxx xxxxxxxxxx, xxxxxxxxxx(xxxxxxx)xxxxxx-1-xxxxx, xxxxxxxx soli, [X-XXX],

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxxx-xxxxxxxxxxx, N-ethyl-N,N-dimethylhexadekan-1-aminium-ethyl-sulfátu, xxxxxxxxxxx-xxxxx-xxxxxxx [XXX],

—

xxxxxxxxxx xx xxx 9. března 2018 xxxxxxx (2XX)-2-[4-(4-xxxxxxxxxxx)-2(xxxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xxx, mefentriflukonazolu,

—

stanovisko xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxx (XXX), 1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx-xxxxx, (X-4)-xxx[1-(xxxxxxx-xxxxx-X)xxxxxxx-2(1X)-xxxxxxx-xxxxx-X]xxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně 3-xxxxx-4-(xxxxxxxxxxx)-1-[3-xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xxx, xxxxxxxxxxxxxxx (XXX),

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně 4,5-dichlor-2-oktyl-2H-isothiazol-3-onu, [XXXXX],

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx 2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xxx, [XXXX],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 ohledně N-(hydroxymethyl)akrylamidu, xxxxxxxxxxxxxxxxxx, [XXX],

—

xxxxxxxxxx ze xxx 15. října 2018 ohledně 5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxxx, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx (XXX), isopropyl [(2S)-3-methyl-1-{[1-(4-methylfenyl)ethyl]amino}-1-oxobutan-2-yl]karbamátu,

—

stanovisko xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (ISO), X-xxxxx-4,5-xxxxxxxx-2(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxx, xxxxxxx [xxxx xxxxxxxx xx xxxxxxx xx xxxxx rostliny Xxxxxxxxxxx indica bez xxxxxxxx, extrahovaný xxxxxxxxxxxxxx xxxxxx uhličitým],

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx kyseliny xxxxxxx …%[X&xx; 70 %],

—

xxxxxxxxxx z 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [X4],

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxx-xxxxxxx (XXX), X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx,

—

xxxxxxxxxx ze 30. listopadu 2018 xxxxxxx fosfinu,

—

stanovisko xx xxx 14. xxxx 2018 ohledně dichlordioktylstannanu,

—

stanovisko xx dne 30. xxxxxxxxx 2018 ohledně 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [DOTE],

—

stanovisko xx xxx 30. listopadu 2018 xxxxxxx xxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx 2-xxxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx m-bis(2,3-epoxypropoxy)benzenu, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx (XXX), xxxxxx 2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 ohledně xxxxxxxxxxxxx (XXX), xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), (RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl-methansulfonátu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2,4-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxx (XXX), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 30. listopadu 2018 xxxxxxx okthilinonu (XXX), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [OIT],

—

stanovisko xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxx (XXX), 3-xxxxxxx-5-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), trans-5-(4-chlorfenyl)-N-cyklohexyl-4-methyl-2-oxo-3-thiazolidin-karboxamidu,

—

stanovisko ze xxx 9. března 2018 ohledně xxxxxxxxxxx (XXX), (X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxx-xxxxx)-1,2,4-xxxxxxx-3(2X)-xxx,

—

xxxxxxxxxx xx xxx 9. března 2018 xxxxxxx xxxxxxxxxxxx (XXX), reakční xxxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthematu,

—

stanovisko xx xxx 14. září 2018 xxxxxxx-xxxxx, xxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxx(α,α-xxxxxxxxxxxxxx)-xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. března 2018 xxxxxxx rozvětveného xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxx 2-(1-(diethylaminohydroxyfenyl) xxxxxxxxx)xxxxxxxx, xxxxx 2-[4-(xxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx.

(3)

Xxxxx xxx x látku xxxxx (číslo CAS 7439–92–1 x indexová xxxxx 082–013–00–1 (xxxxx x prášku; [xxxxxx xxxxxx &xx; 1 xx];) a 082–014–00–7 (xxxxxxxx olovo; [průměr xxxxxx ≥ 1 xx];)), XXX xx xxxx stanovisku xx xxx 30. xxxxxxxxx 2018 navrhl použít xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx xxxxxxxxx i xxxxxxxxx xxxxx. Xxxxx xxxxxxxx x xxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx, xxxxxx xxxxxxxxx xxxxx, ke specifické xxxxxxx výrobě xxxxxx x xxxxxxxx x xxxxx environmentální klasifikaci x xxxxxxxxxx a xxxxxxxxxx xxxxx xxxxxx xxxx v existujících xxxxxxxxx v xxxxxxx XX musí RAC xxxxxxx xxxxx xxxxxxxxx xxxx, zda xx xxx na celistvou x xxxxxxxxx xxxxx xxxxx použita xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx. Xxxxx xxxx byly předloženy xxxx xxxxxxx xxxxxxxx, x xxxxx xxxxxxx, xx xxxxxxxxxxxxxxx xxxxxxxxxxx xxx celistvou formu, xxx ji xxxxxxxxxx xxxxxxxxxx xxxxxx XXX, xxxxxx xxx xxxxxx. Xxxxxxxxxxxxxxx klasifikace xxx xxxxxxxxx xxxxx xxxxx xxxxxx xxxxxxxx xx xxxxxxx VI nařízení (XX) x. 1272/2008, xxxxx XXX xxxxxx xxx možnost xxxxxxxxx xxxxxxxxxx stanovisko.

(4)

Pokud xxx x xxxxx 2-butoxyethanol, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (xxxxx XXX 111-76-2), xxx xxxxx xxxxxxxxxxxxx „akutní xxxxxxxx (xxxxxxxxx)“ xxxx xxxxxxxxxx xxxx vědecké xxxxxxxx, xx kterých xxxxxxx, xx xxxxxxxxxxx xxx xxxx xxxxx xxxxxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxxx xxxxxx XXX, jež xx xxxxxxx xx xxxxxxxx xxxxxxx, nemusí xxx xxxxxx. Xxxx xxxxx xxxxxxxxxxxxx xx xxxxx xxxxxx xxx x xxxxxxx XX xxxxxxxx (XX) č. 1272/2008 xxxxxxx, xxxxx XXX nebude xxx xxxxxxx xxxxxxxxx k xxxxx xxxxx informacím xxxxxxxxxx xxxxxxxxxx; všechny xxxxxxx xxxxx xxxxxxxxxxxxx, x xxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxx RAC, xx xxxxxxxx xxx xxxx.

(5)

Xxxxxxxx (XX) x. 1272/2008 xx xxxxx xxxx xxx xxxxxxxxxxxxx xxxxxxxx xxxxxxx.

(6)

Xxxxxxxxxx xxxxxx xxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx xxxxxx xxx, s výhradou xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxxx ihned, jelikož xxxxxxxxxx xxxxxxxxx xxxxxxx xxxx na to, xxx xxxxxxxxxxxx xxxxxxxxxx x balení látek x xxxxx xxxxx xxxx xxxxxxxxxxx xxxxxxxxxxxx x xxxxxxx stávající xxxxxx. Xxxx doba xx rovněž xxxxxxxx x tomu, aby xxxxxxxxxx xxxx xxxxxxxx xxxx xxxxxxxx xxxxxxxx xxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxx, které xxxxxxxx v důsledku xxxx provedených xxxxx xxxxxx xxxxxxxx. Xxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx x xx. 22 xxxx. 1 xxxx. x) xxxxxxxx Evropského parlamentu x Rady (ES) x. 1907/2006 (3) nebo xxxxxxxxx xxxxxxxxx v xxxxxx 50 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 528/2012&xxxx;(4).

(7)

Xxxxxxxxxxx by xxxx xxxx xxx xxxxxxxx, xxx xxxxx nová xxxxxxxxxx týkající xx xxxxxxxxxxx, xxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx dnem xxxxxxxxxxxxx xxxxxx nařízení. Xx xx v souladu x xxxxxxxxx podle xx. 61 odst. 2 xxxxxxxx (XX) x. 1272/2008,

XXXXXXX XXXX XXXXXXXX:

Xxxxxx 1

Xxxxx xxxxxxxx (XX) x. 1272/2008

Tabulka 3 x xxxxx 3 přílohy XX xxxxxxxx (ES) x. 1272/2008 se xxxx x xxxxxxx x xxxxxxxx xxxxxx xxxxxxxx.

Xxxxxx 2

Xxxxx x xxxxxxxx a použitelnost

Toto xxxxxxxx vstupuje v xxxxxxxx xxxxxxxx xxxx xx xxxxxxxxx x Xxxxxxx věstníku Xxxxxxxx xxxx.

Xxxxxxx se xxx xxx 1. března 2022.

Xxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xxxxxx xxxxx xxx xxxxx x xxxxx klasifikovány, xxxxxxxxxx x baleny x souladu x xxxxxxxxx (XX) x. 1272/2008 ve xxxxx xxxxxx xxxxxxxx xxxxx xxxxx dnem 1. xxxxxx 2022.

Xxxx nařízení xx xxxxxxx x xxxxx xxxxxxx x xxxxx xxxxxxxxxx xx xxxxx xxxxxxxxx xxxxxxx.

X Bruselu xxx 19. xxxxxx 2020.

Xx Komisi

Ursula XXX XXX XXXXX

xxxxxxxxxxx

(1)&xxxx;&xxxx;xxxxXx. xxxx. X 353, 31.12.2008, x. 1.

(2)&xxxx;&xxxx;Xxxxxxxxxx xxxx xxxxxxxx na xxxx xxxxxxxxxxx xxxxxxx: xxxxx://xxxx.xxxxxx.xx/xxxxxxxx-xx-xxx-xxxxxxxxxx-xxxxx-xxxxxxx/-/xxxxxxx/xxxx/-/xxXxxxxx/-/xxxXxxxxx/-/xxx_xxxxxxxXxxx/-/xxx_xxxxxxxXx/-/xxx_xxxxxx_xxxxxx/Xxxxxxx+Xxxxxxx/xxx_xxxxxxxxxXxxx/-/xxx_xxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxx/-/xxx_xxxxxxxxx/-/xxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxxxxXx/-/xxx_xxxxxxxxxx_xxxxxxxxx/-/

(3)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx parlamentu a Xxxx (XX) x. 1907/2006 xx xxx 18. xxxxxxxx 2006

x xxxxxxxxxx, hodnocení, povolování x omezování chemických xxxxx, x xxxxxxx Xxxxxxxx agentury pro xxxxxxxx xxxxx, o xxxxx xxxxxxxx 1999/45/XX x x xxxxxxx xxxxxxxx Xxxx (XXX) x. 793/93, nařízení Xxxxxx (ES) x. 1488/94, xxxxxxxx Xxxx 76/769/XXX x xxxxxxx Xxxxxx 91/155/XXX, 93/67/XXX, 93/105/XX x 2000/21/XX (Xx. xxxx. L 396, 30.12.2006, s. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 528/2012 xx xxx 22. května 2012

x xxxxxxxx biocidních xxxxxxxxx na xxx x jejich xxxxxxxxx

(Xx. xxxx. L 167, 27.6.2012, s. 1).

XXXXXXX

X příloze XX xxxxxxxx (XX) x. 1272/2008 xx xxxxxxx 3 x xxxxx 3 xxxx xxxxx:

1)

Xxxxxxxx xx xxxx xxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx název

Číslo XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x XXX

Xxxxxxxx

Xxxx tříd a xxxxxxxxx xxxxxxxxxxxxx

Xxxx standardních xxx o nebezpečnosti

Kódy xxxxxxxxxxx xxxxxxx x xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx vět x xxxxxxxxxxxxx

„007-030-00-3

xxxxxxxx dusičná …% [C ≤ 70 %]

231-714-2

7697-37-2.

Xx. Xxx. 3

Xxxxx Tox. 3

Xxxx Xxxx. 1 X

X272

X331

X314

XXX03

XXX06

XXX05

Xxx

X272

X331

X314

XXX071

Xx. Xxx. 3; X272: X ≥ 65 %

xxxxxxxxx: XXX = 2,65 mg/l (páry)

Skin Xxxx. 1 X; X314: C ≥ 20 %

Skin Xxxx. 1X; X314: 5 % ≤ X &xx; 20 %

X“

„014-048-00-5

xxxxxx x xxxxxxx křemíku (x xxxxxxx < 3 μm, xxxxx &xx; 5 μx x x xxxxxxx xxxxx ≥ 3:1)

206-991-8

409-21-2

308076-74-6

Xxxx. 1X

X350x

XXX08

Xxx

X350x“

„014-049-00-0

xxxxxxxxxxxxxxxxxxxx; trimethoxy(vinyl)silan

220-449-8

2768-02-7

Skin Xxxx. 1X

X317

XXX07

Xxx

X317“

„014-050-00-6

xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx;

6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx

213-934-0

1067-53-4

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„016-098-00-3

xxxxxxxx-xxxxxxxx

210-871-0

624-92-0

Xxxx. Xxx. 2

Xxxxx Tox. 3

Xxxxx Xxx. 3

STOT XX 3

XXXX SE 1

Eye Xxxxx. 2

Xxxx Xxxx. 1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X225

X331

X301

X336

X370 (xxxxx xxxxxxx xxxxx, xxxxxxxxx)

X319

X317

X400

X410

XXX02

XXX06

XXX08

XXX09

Xxx

X225

X331

X301

X336

X370 (xxxxx dýchací xxxxx, xxxxxxxxx)

X319

X317

X410

xxxxxxxxx: XXX = 5 xx/x (xxxx)

xxxxxx: XXX = 190 xx/xx TH

M = 1

X = 10“

„029-024-00-X

xxxxxxxxxxx xxx;

[xxxxx xxxxxx: xx 0,9 xx x xx 6,0 xx; xxxxx částic: od 0,494 xx 0,949 xx]

231-159-6

7440-50-8

Xxxxxxx Xxxxxxx 2

X411

XXX09

X411“

„029-025-00-5

xxx(X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)xxx;

xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxx;

[Xx-XXX]

239-703-4

312600-89-8

15627-09-5

Xxxx. Xxx. 1

Acute Tox. 4

XXXX XX 2

Xxx Xxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X228

X302

X373 (xxxxx)

X318

X400

X410

XXX02

XXX07

XXX08

XXX05

XXX09

Xxx

X228

X302

X373 (xxxxx)

X318

X410

xxxxxx: XXX = 360 mg/kg XX

X = 1

M = 1“

„050-031-00-9

xxxxxxxxxx-xxxxxxxx; [1]

stannan, xxxxxxx-, xxx(xxxx acyloxy) xxxxxxxx [2]

222-883-3 [1] 293-901-5 [2]

3648-18-8 [1] 91648-39-4 [2]

Xxxx. 1B

STOT XX 1

X360X

X372 (xxxxxxxx xxxxxx)

XXX08

Xxx

X360X

X372 (imunitní xxxxxx)“

„601-092-00-0

xxxxxxx[xxx,x]xxxxxxx;

xxxxxxx[x,x]xxxxx

205-886-4

191-30-0

Xxxx. 1X

Xxxx. 2

X350

X341

XXX08

Xxx

X350

X341

Xxxx. 1B; X350: X ≥ 0,001 %“

„603-237-00-3

ipkonazol (ISO);

(1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorbenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyklopentanol

–

125225-28-7

115850-69-6

115937-89-8

Repr. 1X

Xxxxx Tox. 4

XXXX XX 2

Aquatic Chronic 1

X360X

X302

X373 (xxx, xxxx, xxxxx)

X410

XXX08

XXX07

XXX09

Xxx

X360X

X302

X373 (oči, xxxx, xxxxx)

X410

xxxxxx: XXX = 500 xx/xx XX

X = 100“

„603-238-00-9

xxx(2-(2-xxxxxxxxxxxxx)xxxxx)-xxxxx; xxxxxxxxx

205-594-7

143-24-8

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„603-239-00-4

xxxxxxxxxxxxx (XXX);

(2XX,3XX)-1-(4-xxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xx

–

76738-62-0

Xxxx. 2

Xxxxx Xxx. 4

Xxxxx Xxx. 4

Xxx Irrit. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X361x

X332

X302

X319

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X302

X319

X410

xxxxxxxxx: ATE = 3,13 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 490 xx/xx XX

X = 10

M = 10“

„603-240-00-X

2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxx

221-967-7

3296-90-0

Xxxx. 1X

Xxxx. 1X

X350

X340

XXX08

Xxx

X350

X340“

„603-241-00-5

xxxxxxxx;

(2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx

203-377-1

106-24-1

Xxxx Xxxx. 1

X317

XXX07

Xxx

X317“

„605-041-00-3

2-(4-xxxx-xxxxxxxxxxx)xxxxxxxx

201-289-8

80-54-6

Xxxx. 1X

X360Xx

XXX08

Xxx

X360Xx“

„607-738-00-8

XXXX-xxxxxxxxx (ISO);

S-ethyl (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxx; X-xxxxx 4-chlor-o-tolyloxythioacetát

246-831-4

25319-90-8

Acute Xxx. 4

XXXX XX. 2

Aquatic Xxxxx 1 Xxxxxxx Xxxxxxx 1

H302

H373 (játra)

H400

H410

GHS07

GHS08

GHS09

Wng

H302

H373 (xxxxx)

X410

xxxxxx: ATE = 450 xx/xx TH

M = 10

M = 10“

„607-740-00-9

xxxxxxxxxx-xxxxxx

248-523-5

27554-26-3

Xxxx. 1B

H360FD

GHS08

Dgr

H360FD“

„607-741-00-4

4-{[(6-chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on; xxxxxxxxxxxxxx

–

951659-40-8

Xxxxx Xxx. 4

XXXX RE 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H302

H373 (xxxxxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxxxxxx)

X410

xxxxxx: XXX = 500 xx/xx TH

M = 10

X = 10“

„607-742-00-X

xxxxxxxxxxxxx-xxxxxx (ISO);

methyl-4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)karbonylsulfamoyl]-5-methylthiofen-3-karboxylát

–

317815-83-1

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X400

X410

XXX09

Xxx

X410

X = 1000

M = 1000“

„607-743-00-5

X-(+)-xxxxxx xxxxxxxx;

(2 X)-2-xxxxxxxxxxxxxxxx xxxxxxxx

201-196-2

79-33-4

Xxxx Xxxx. 1C

Eye Xxx. 1

X314

X318

XXX05

Xxx

X314

XXX071“

„607-744-00-0

2-xxxxxxxxxxxxxxxxxxx

221-499-3

3121-61-7

Xxxx. Xxx. 3

Xxxx. 2

Repr. 1X

Xxxxx Xxx. 3

Xxxxx Xxx. 4

Xxxx Corr. 1X

Xxx Xxx. 1

Xxxx Xxxx. 1

X226

X341

X360XX

X331

X302

X314

X318

X317

XXX02

XXX05

XXX06

XXX08

Xxx

X226

X341

X360XX

X331

X302

X314

X317

XXX071

xxxxxxxxx: XXX = 2,7 xx/x (xxxx)

xxxxxx: XXX = 404 xx/xx XX“

„607-745-00-6

xxxxxxxxxx kyselina …%

206-058-5

298-12-4

Xxx Dam. 1

Xxxx Xxxx. 1X

X318

X317

XXX05

XXX07

Xxx

X318

X317

X“

„607-746-00-1

xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx;

[xxxxxxxxxxx uvolněný x xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx]

274-357-8

70161-44-3

Xxxx. 1X

Xxxx. 2

Xxxxx Xxx. 4

Xxxxx Xxx. 4

XXXX SE 3

Xxxx Irrit. 2

Xxx Xxxxx. 2

Xxxx Sens. 1

X350

X341

X332

X302

X335

X315

X319

X317

XXX08

XXX07

Xxx

X350

X341

X332

X302

X335

X315

X319

X317

xxxxxxxxx: XXX = 3 mg/l (prach xxxx mlha)

orální: XXX = 1 100 xx/xx XX

8

9“

„611-181-00-6

(xxxxx-XXX-xxxxx)xxxxxxxxxx xxxxxxxx;

xxxxxxxxxxxxxxxxxxxxxxx-1-xxxx, xxxxxxxx xxx;

[X-XXX]

–

66603-10-9

Xxxx. Xxx. 1

Acute Xxx. 3

XXXX XX 2

Xxxx Irrit. 2

Xxx Xxx. 1

Aquatic Xxxxxxx 2

X228

X301

X373 (xxxxx)

X315

X318

X411

XXX02

XXX06

XXX08

XXX05

XXX09

Xxx

X228

X301

X373 (xxxxx)

X315

X318

X411

xxxxxx: XXX = 136 xx/xx XX“

„612-294-00-3

xxxxxxxxxxxxxxxxxxxxx;

X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxx;

xxxxxxxxxxx-xxxxx-xxxxxx;

[XXX]

221-106-5

3006-10-8

Xxxx Corr. 1

Xxx Dam. 1

Aquatic Xxxxx 1

Aquatic Xxxxxxx 1

X314

X318

X400

X410

XXX05

XXX09

Xxx

X314

X410

XXX071

X = 100

M = 1&xxxx;000 “

„613-331-00-6

(2XX)-2-[4-(4-xxxxxxxxxxx)-2-(xxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xx;

xxxxxxxxxxxxxxxxxx

–

1417782-03-6

Xxxx Xxxx. 1

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X317

X400

X410

XXX07

XXX09

Xxx

X317

X410

X = 1

M = 1“

„613-332-00-1

xxxxxxxxxxxxxxx (ISO);

1-(4-{4-[5-(2,6-difluorfenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluormethyl)-1H-pyrazol-1-yl]ethanon

–

1003318-67-9

Aquatic Xxxxxxx 1

X410

XXX09

Xxx

X410

X = 1“

„613-333-00-7

xxxxxxxxx-xxxxx; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx

236-671-3

13463-41-7

Xxxx. 1X

Xxxxx Xxx. 2

Xxxxx Xxx. 3

STOT XX 1

Xxx Xxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360X

X330

X301

X372

X318

X400

X410

XXX08

XXX06

XXX05

XXX09

Xxx

X360X

X330

X301

X372

X318

X410

xxxxxxxxx: ATE = 0,14 mg/l (xxxxx nebo xxxx)

xxxxxx: XXX = 221 xx/xx XX

X = 1&xxxx;000

X = 10“

„613-334-00-2

flurochloridon (XXX);

3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx

262-661-3

61213-25-0

Xxxx. 1B

Acute Xxx. 4

Xxxx Xxxx. 1

Aquatic Xxxxx 1

Aquatic Xxxxxxx 1

X360XX

X302

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X360XX

X302

X317

X410

xxxxxx: XXX = 500 xx/xx TH

M = 100

X = 100“

„613-335-00-8

4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [XXXXX]

264-843-8

64359-81-5

Xxxxx Xxx. 2

Xxxxx Tox. 4

Xxxx Xxxx. 1

Xxx Xxx. 1

Xxxx Xxxx. 1 X

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X330

X302

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X302

X314

X317

X410

XXX071

xxxxxxxxx: ATE = 0,16 xx/x (xxxxx nebo mlha)

orální: XXX = 567 xx/xx TH

Skin Xxxxx. 2; H315: 0,025 % ≤ X &xx; 5 %

Xxx Xxxxx. 2; H319: 0,025 % ≤ X &xx; 3 %

Xxxx Sens. 1 X; X317: C ≥ 0,0015 %

X = 100

M = 100“

„613-336-00-3

2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx;

[XXXX]

–

2527-66-4

Xxxxx Xxx. 4

Xxxxx Xxx. 3

Xxxx Xxxx. 1X

Xxx Xxx. 1

Xxxx Xxxx. 1 X

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 2

X312

X301

X314

X318

X317

X400

X411

XXX06

XXX05

XXX09

Xxx

X312

X301

X314

X317

X410

XXX071

xxxxxxxx: ATE = 1&xxxx;100 xx/xx XX

xxxxxx: XXX = 175 xx/xx XX

Xxxx Sens. 1 A; X317: X ≥ 0,0015 %

X = 1“

„616-228-00-4

3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’-xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxx;

xxxxxxxxxxxx

–

907204-31-3

Xxxx.

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X362

X400

X410

XXX09

Xxx

X362

X410

X = 1

M = 1“

„616-230-00-5

X-(xxxxxxxxxxxxx)xxxxxxxxx; methylolakrylamid; [XXX]

213-103-2

924-42-5

Xxxx. 1X

Xxxx. 1B

STOT XX 1

X350

X340

X372 (xxxxxxxxx xxxxxxx xxxxxx)

XXX08

Xxx

X350

X340

X372 (periferní xxxxxxx xxxxxx)“

„616-231-00-0

5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxx; 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxx;

xxxxxxxxx

–

494793-67-8

Xxxx. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X351

X400

X410

XXX08

XXX09

Xxx

X351

X410

X = 1

X = 1“

„616-232-00-6

xxxxxxxxxxxx (XXX);

xxxxxxxxx [(2S)-3-methyl-1-{[1-(4-methylfenyl)ethyl]amino}-1-oxobutan-2-yl]karbamát

–

140923-17-7

Carc. 2

X351

XXX08

Xxx

X351“

„616-233-00-1

xxxxxxxxxx (XXX);

X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

–

175217-20-6

XXXX XX 2

Xxxxxxx Xxxxxxx 2

X373

X411

XXX08

XXX09

Xxx

X373

X411“

„650-057-00-6

Xxxxxxx, xxxxxxx [xxxx xxxxxxxx xx xxxxxxx xx xxxxx xxxxxxxx Azadirachta xxxxxx xxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx xxxxxxxxx]

283-644-7

84696-25-3

Xxxxxxx Xxxxxxx 3

H412

H412“

2)

položky odpovídající xxxxxxxxx xxxxxx 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 a 617–006–00-X se xxxxxxxxx xxxxxx xxxxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx CAS

Klasifikace

Označení

Specifické xxxxxxx. xxxxxx, multiplikační xxxxxxx x XXX

Xxxxxxxx

Xxxx xxxx x xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx x signálních xxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

„007-004-00-1

xxxxxxxx xxxxxxx …% [X > 70 %]

231-714-2

7697-37-2

Xx. Xxx. 2

Xxxxx Xxx. 1

Xxxx Xxxx. 1 X

X272

X330

X314

XXX03

XXX06

XXX05

Xxx

X272

X330

X314

XXX071

Xx. Xxx. 2; X272: X ≥ 99 %

Xx. Xxx. 3; X272: 70 % ≤ X < 99 %

X“

„014-018-00-1

xxxxxxxxxxxxxxxxxxxxxxxxxxx;

[X4]

209-136-7

556-67-2

Xxxx. 2

Aquatic Chronic 1

X361x ***

H410

GHS08

GHS09

Wng

H361f ***

X410

X = 10“

„015-134-00-5

pirimifos-methyl (ISO);

O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforothioát

249-528-5

29232-93-7

Acute Xxx. 4

STOT XX 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X302

X372 (xxxxxxx xxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X372 (xxxxxxx xxxxxx)

X410

xxxxxx: XXX = 1&xxxx;414 xx/xx XX

X = 1&xxxx;000

X = 1&xxxx;000 “

„015-181-00-1

xxxxxx

232-260-8

7803-51-2

Xxxx. Xxx 1

Xxxxx. Xxx

Xxxxx Xxx. 1

Xxxx Xxxx. 1B

Aquatic Xxxxx 1

X220

X330

X314

X400

XXX02

XXX04

XXX06

XXX05

XXX09

Xxx

X220

X330

X314

X400

xxxxxxxxx:

XXX = 10 xxxX (xxxxx)

X“

„050-021-00-4

xxxxxxxxxxxxxxxxxxxxx

222-583-2

3542-36-7

Xxxx. 1X

Xxxxx Xxx. 2

STOT RE 1

Xxxxxxx Xxxxxxx 3

X360X

X330

X372 **

X412

XXX08

XXX06

Xxx

X360X

X330

X372 **

H412

Repr. 1B; X360 D: C ≥ 0,03 %

inhalační: XXX = 0.098 xx/X (xxxxx xxxx xxxx)“

„050-027-00-7

2-xxxxxxxxxx 10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxxxxxxxxxx; [XXXX]

239-622-4

15571-58-1

Xxxx. 1X

XXXX RE 1

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360X

X372 (xxxxxxxx xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X360X

X372 (xxxxxxxx xxxxxx)

X410“

„082-013-00-1

xxxxxxx xxxxxx; [xxxxxx xxxxxx &xx; 1 xx]

231-100-4

7439-92-1

Xxxx. 1 X

Xxxx.

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

H360FD

H362

H400

H410

GHS08

GHS09

Dgr

H360FD X362

X410

Xxxx. 1 X; X360X: X ≥ 0,03 %

X = 1

X = 10“

„603-014-00-0

2-xxxxxxxxxxx-1-xx;

xxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-905-0

111-76-2

Xxxxx Xxx. 4*

Xxxxx Xxx. 4

Skin Xxxxx. 2

Eye Xxxxx. 2

X332

X302

X315

X319

XXX07

Xxx

X332

X302

X315

X319

xxxxxx: ATE = 1&xxxx;200 xx/xx TH“

„603-065-00-9

m-bis(2,3-epoxypropoxy)benzen;

resorcinoldiglycidylether

202-987-5

101-90-6

Carc. 1X

Xxxx. 2

Acute Tox. 3

Xxxxx Xxx. 4

Skin Xxxxx. 2

Xxx Xxxxx. 2

Xxxx Xxxx. 1

Aquatic Xxxxxxx 3

H350

H341

H311

H302

H315

H319

H317

H412

GHS08

GHS06

Dgr

H350

H341

H311

H302

H315

H319

H317

H412

dermální: XXX = 300 mg/kg XX orální: XXX = 500 xx/xx XX“

„607-177-00-9

xxxxxxxxxx-xxxxxx (XXX);

xxxxxx-2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxx

401-190-1

101200-48-0

XXXX RE 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X373

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X373

X317

X410

X = 100

X = 100“

„607-256-00-8

azoxystrobin (XXX);

xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx

–

131860-33-8

Xxxxx Xxx. 3

Aquatic Xxxxx 1

Aquatic Xxxxxxx 1

X331

X400

X410

XXX06

XXX09

Xxx

X331

X410

xxxxxxxxx:

XXX = 0,7 xx/x (xxxxx xxxx xxxx)

X = 10

X = 10“

„607-314-00-2

xxxxxxxxxxx (ISO);

(RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl xxxxxxxxxxxxxx

247-525-3

26225-79-6

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

H400

H410

GHS09

Wng

H410

M = 1

X = 1“

„609-041-00-4

2,4-dinitrofenol

200-087-7

51-28-5

Acute Xxx. 3 *

Xxxxx Xxx. 3

Xxxxx Tox. 2

XXXX RE 1

Aquatic Xxxxx 1

X331

X311

X300

X372

X400

XXX06

XXX08

XXX09

Xxx

X331

X311

X300

X372

X400

xxxxxxxx: XXX = 300 xx/xx XX xxxxxx: XXX = 30 mg/kg XX“

„609-064-00-X

xxxxxxxxx (XXX);

2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxx

–

104206-82-8

Xxxx. 2

XXXX XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H361d

H373 (xxx, xxxxxxx xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X361x

X373 (xxx, xxxxxxx xxxxxx)

X410

X = 10

X = 10“

„613-112-00-5

xxxxxxxxxx (XXX);

2-xxxxx-2X-xxxxxxxxxx-3-xx; [XXX]

247-761-7

26530-20-1

Xxxxx Xxx. 2

Acute Tox. 3

Xxxxx Xxx. 3

Xxxx Xxxx. 1

Xxx Xxx. 1

Xxxx Xxxx. 1 X

Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1

X330

X311

X301

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X311

X301

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,27 xx/x (prach xxxx xxxx)

xxxxxxxx: XXX = 311 xx/xx TH xxxxxx: ATE = 125 mg/kg XX

Xxxx Xxxx. 1 X; X317: X ≥ 0,0015 %

X = 100

X = 100“

„613-115-00-1

xxxxxxxxx (XXX);

3-xxxxxxx-5-xxxxxxxxxxxxxx

233-000-6

10004-44-1

Xxxx. 2

Acute Xxx. 4

Xxx Dam. 1

Xxxx Xxxx. 1

Xxxxxxx Xxxxxxx 2

X361x

X302

X318

X317

X411

XXX08

XXX07

XXX05

XXX09

Xxx

X361x

X302

X318

X317

X411

xxxxxx: XXX = 1&xxxx;600 xx/xx TH“

„613-125-00-6

hexythiazox (XXX);

xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx

–

78587-05-0

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„613-202-00-4

xxxxxxxxxx (XXX);

(X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx

–

123312-89-0

Xxxx. 2

Xxxx. 2

Aquatic Xxxxxxx 1

X351

X361xx

X410

XXX08

XXX09

Xxx

X351

X361xx

X410

X = 1“

„613-259-00-5

xxxxxxxxxxx (ISO);

reakční xxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemát

428-790-6

72963-72-5

Carc. 2

Xxxxx Xxx. 4

Xxxxx Xxx. 4

XXXX XX 2

Aquatic Xxxxx 1

Aquatic Xxxxxxx 1

X351

X332

X302

X371 (xxxxxxx systém; xxxxxx, xxxxxxxxx)

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X332

X302

X371 (nervový xxxxxx; xxxxxx, xxxxxxxxx)

X410

xxxxxxxxx: XXX = 1,4 xx/x (prach nebo xxxx)

xxxxxx: ATE = 550 xx/xx XX

X = 10

X = 10“

„616-014-00-0

xxxxx-xx-xxxx; xxxxxxxxxxxxxxxxxx, ethyl(methyl)ketonoxim

202-496-6

96-29-7

Carc. 1X

Xxxxx Tox. 4

Xxxxx Xxx. 3

XXXX SE 3

XXXX XX 1

XXXX XX 2

Skin Xxxxx. 2

Xxx Dam. 1

Xxxx Xxxx. 1

X350

X312

X301

X336

X370 (xxxxx xxxxxxx xxxxx)

X373 (xxxxxx xxxx)

X315

X318

X317

XXX08

XXX06

XXX05

Xxx

X350

X312

X301

X336

X370 (xxxxx xxxxxxx xxxxx)

X373 (xxxxxx oběh)

H315

H318

H317

dermální: XXX = 1&xxxx;100 xx/xx XX orální: XXX = 100 xx/xx XX“

„617-006-00-X

xxx(α,α-xxxxxxxxxxxxxx)xxxxxxx

201-279-3

80-43-3

Xxx. Xxxxx. X

Xxxx. 1B

Skin Xxxxx. 2

Xxx Irrit. 2

Xxxxxxx Xxxxxxx 2

X242

X360X

X315

X319

X411

XXX02

XXX08

XXX07

XXX09

Xxx

X242

X360X

X315

X319

X411“

3)

xxxxxxx odpovídající xxxxxxxxx číslům 601-064-00-8 x 607-693-00-4 se xxxxxxx.